← All trials
NCT04616456
Early Phase 1Interventional
Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies).
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2020
- Primary completion
- Jun 30, 2022
- Completion date
- Jun 30, 2022
- First posted
- Nov 5, 2020
- Last posted
- Dec 24, 2020
- Enrollment
- 8
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityStudy director
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityReponsible party - principal investigator
- Biohaven Pharmaceuticals Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.